Selective Alpha-7 nAChR Agonists for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing alpha-7 nicotinic acetylcholine receptor (nAChR) agonists often cause significant side effects due to their non-selectivity, and there is a need for compounds that can enhance cognition and ameliorate cognitive impairments such as Mild Cognitive Impairment (MCI) and mild Alzheimer's Disease without these adverse effects.
Innovation Solution
The use of selective alpha-7 nAChR agonists, particularly (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or its metabolites or pharmaceutically acceptable salts, administered in therapeutically effective amounts, to activate the alpha-7 nAChR and improve cognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective nAChR agonists are used to enhance cognition, then cognitive function is improved, but side effects increase significantly
Solution Approach 1:
The patent applies local quality by designing agonists with selective affinity for specific nAChR subtypes (alpha7, alpha4beta2, ganglionic) rather than acting on all nAChR subtypes uniformly. This subtype-selective approach allows cognitive enhancement through targeted receptor activation while avoiding side effects associated with non-selective activation of other receptor subtypes.
Solution Approach 2:
The patent employs parameter changes by optimizing the EC50 values and affinity ratios for different nAChR subtypes. The agonists are designed with specific affinity profiles (e.g., at least 10-fold, 20-fold, or 50-fold selectivity) to achieve therapeutic effects at controlled doses while minimizing off-target effects that cause side effects.
2Object-generated harmful factors
If selective alpha-7 nAChR agonists are used to reduce side effects, then side effects are minimized, but cognitive enhancement efficacy may be reduced
Solution Approach 1:
The patent applies local quality by designing agonists with selective affinity for specific nAChR subtypes (alpha7, alpha4beta2, ganglionic) rather than acting on all nAChR subtypes uniformly. This subtype-selective approach allows cognitive enhancement through targeted receptor activation while avoiding side effects associated with non-selective activation of other receptor subtypes.
Solution Approach 2:
The patent employs parameter changes by optimizing the EC50 values and affinity ratios for different nAChR subtypes. The agonists are designed with specific affinity profiles (e.g., at least 10-fold, 20-fold, or 50-fold selectivity) to achieve therapeutic effects at controlled doses while minimizing off-target effects that cause side effects.
3Reliability
If high affinity agonists are used to improve cognition, then cognitive enhancement is increased, but toxicity and irritation increase
Solution Approach 1:
The patent employs parameter changes by optimizing the EC50 values and affinity ratios for different nAChR subtypes. The agonists are designed with specific affinity profiles (e.g., at least 10-fold, 20-fold, or 50-fold selectivity) to achieve therapeutic effects at controlled doses while minimizing off-target effects that cause side effects.
Solution Approach 2:
The patent uses intermediary by introducing selective agonists that act as mediators between the therapeutic goal (cognitive enhancement) and the biological system (nAChR receptors). These selective agonists provide a buffer that achieves cognitive benefits while filtering out the harmful effects associated with non-selective high-affinity agonists.
Data Source
AI summary
Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a metabolite or a pharmaceutically acceptable salt thereof to the individual.